ATX THERAPEUTICS
ATX Therapeutics is a digital health company that empowers people to reach their health goals by enabling healthy behavior changes in individuals who either have, or are at risk of developing chronic diseases, such as cancer, heart disease and chronic obstructive pulmonary disease (COPD). Working with healthcare consumers, providers, researchers, health plans and employers, ATX Therapeutics creates evidence-based digital therapeutic products that deliver positive health outcomes while engaging patients to manage specific chronic health conditions and their associated risk behaviors. The company follows a human-centered and data-driven approach to product design, combining exceptional consumer-grade experiences with clinically-validated interventions to deliver sustainable results.
ATX THERAPEUTICS
Industry:
Health Care
Founded:
2019-07-23
Address:
Austin, Texas, United States
Country:
United States
Website Url:
http://www.atxtherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
8154049424
Email Addresses:
[email protected]
Technology used in webpage:
Gravatar Profiles U.S. Server Location
Similar Organizations
PolyFins Technology Inc
Digital therapeutic apps for chronic skin diseases
Tiatros Inc.
Digital Therapeutics for Behavioral Health
Founder
Official Site Inspections
http://www.atxtherapeutics.com
Unable to get host informations!!!

More informations about "ATX Therapeutics"
ATXA Therapeutics - Innovation
ATXA Therapeutics is a clinical-stage pharmaceutical company committed to the advancement of innovative, life-changing treatments for cardiopulmonary diseases. Our research focuses on developing novel antagonists of the …See details»
ATXA Therapeutics - Crunchbase Company Profile
Contact Email [email protected] ATXA Therapeutics Limited is a spin-out company from University College Dublin whose primary focus is to …See details»
ATXA Therapeutics - LinkedIn
ATXA Therapeutics is a clinical-stage pharmaceutical company committed to the advancement of innovative, life-changing treatments for cardiopulmonary diseases.See details»
ATXA Therapeutics - PitchBook
ATXA Therapeutics General Information Description. Developer of a clinical-stage pharma company intended for heart and lung conditions that target human thromboxane receptor …See details»
ATXA Therapeutics Ltd - European Commission
Pharmaceutical company focused on the small molecule drug NTP42 for the treatment of pulmonary arterial hypertension (PAH).See details»
ATXA Therapeutics - Overview, News & Similar companies
ATXA Therapeutics contact info: Phone number: +353 877765446 Website: www.atxatherapeutics.com What does ATXA Therapeutics do? ATXA Therapeutics is …See details»
ATXA Therapeutics - About Us
Founded by Professor Therese Kinsella in 2015, ATXA is the culmination of over 20 years of research and extensive, prestigious funding, along with a proven record in elucidating the …See details»
ATXA Therapeutics Information - RocketReach
Atxatherapeutics.com; 1 416357XXXX; View Similar People. Related Companies Maple Clinic. 6 Results Fitness. 7 $5m Learn More How It Works. Get a Free Account. Sign up for a free …See details»
Atxa Therapeutics Ltd. - Drug pipelines, Patents, Clinical trials
Explore Atxa Therapeutics Ltd. with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, and 5 literature, Disease Domain:Neoplasms ...See details»
ATX Therapeutics - Crunchbase Company Profile & Funding
ATX Therapeutics is a digital health company that empowers people to reach their health goals by enabling healthy behavior changes in individuals who either have, or are at risk of developing …See details»
ATXA Therapeutics Overview | SignalHire Company Profile
Organization Website: atxatherapeutics.com : Phone Number +353 1 525 2829: ATXA Therapeutics industries Pharma: Headquarters Location: UCD Conway Institute, Belfield, …See details»
Atxa Therapeutics Ltd. (Atxa Therapeutics Ltd.) - 药物管线_专利_临 …
May 7, 2025 Abstract Background NTP42 is a novel antagonist of the thromboxane prostanoid receptor (TP), currently in development for the treatment of pulmonary arterial hypertension …See details»
ATXA Therapeutics - Our Team
The ATXA team has strong expertise in cardiovascular and cancer biology with technical know-how in platelet biology, cellular and molecular biology, protein biology, pathological and …See details»
ATXA Therapeutics Ltd - VentureRadar
ATXA Therapeutics Limited is focusing on clinical development of novel small molecule drugs to treat Pulmonary Arterial Hypertension (PAH), serving a... ... Find out ...See details»
ATXA Therapeutics Appoints Dr Ivan Coulter as Chief Executive …
Www.atxatherapeutics.com. Pulmonary Arterial Hypertension(PAH) is one form of a broader condition known as pulmonary hypertension, which means high blood pressure in the lungs. In …See details»
ATXA Therapeutics - Our Mission
Driven by innovative research, our aim is to bring accessible, affordable and life-changing treatments to patients with cardiopulmonary diseases, offering them new hope and bettering …See details»
ATXA Therapeutics - News
ATXA will present data from a First-in-Human (FIH) Phase I trial of NTP42:KVA4, a novel formulation of its lead clinical candidate NTP42...See details»
ATXA to Present at ATS International Conference 2023
Apr 28, 2023 ATXA will present data from a First-in-Human (FIH) Phase I trial of NTP42:KVA4, a novel formulation of its lead clinical candidate NTP42 at the American Thoracic Society (ATS) …See details»
ATXA Therapeutics - Our Pipeline
ATXA Therapeutics has developed a novel series of highly selective antagonists of the TP receptor. Amongst ATXA’s TP antagonist series is the lead candidate drug NTP42, as well as …See details»
AtG - stopping cancer metabolic adaptation
Where to find AtG Hospital Duran i Reynals (3rd floor). Av. Gran via 199, 08908. Barcelona, Spain. Call us at +34 932 607 252See details»